NZ270039A - 4-phenylpiperidino propanoic acid derivatives and medicaments - Google Patents

4-phenylpiperidino propanoic acid derivatives and medicaments

Info

Publication number
NZ270039A
NZ270039A NZ270039A NZ27003994A NZ270039A NZ 270039 A NZ270039 A NZ 270039A NZ 270039 A NZ270039 A NZ 270039A NZ 27003994 A NZ27003994 A NZ 27003994A NZ 270039 A NZ270039 A NZ 270039A
Authority
NZ
New Zealand
Prior art keywords
compound
crystalline
formula
alkyl
salt
Prior art date
Application number
NZ270039A
Other languages
English (en)
Inventor
Scott Alan Frank
Douglas Edward Prather
Jeffrey Alan Ward
John Arnold Werner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ270039A publication Critical patent/NZ270039A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ270039A 1993-12-08 1994-12-01 4-phenylpiperidino propanoic acid derivatives and medicaments NZ270039A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/164,074 US5434171A (en) 1993-12-08 1993-12-08 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Publications (1)

Publication Number Publication Date
NZ270039A true NZ270039A (en) 1996-08-27

Family

ID=22592858

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ270039A NZ270039A (en) 1993-12-08 1994-12-01 4-phenylpiperidino propanoic acid derivatives and medicaments

Country Status (30)

Country Link
US (1) US5434171A (cg-RX-API-DMAC10.html)
EP (3) EP0984004A3 (cg-RX-API-DMAC10.html)
JP (2) JP3834075B2 (cg-RX-API-DMAC10.html)
KR (1) KR100356239B1 (cg-RX-API-DMAC10.html)
CN (2) CN1057294C (cg-RX-API-DMAC10.html)
AT (1) ATE200279T1 (cg-RX-API-DMAC10.html)
AU (1) AU681198B2 (cg-RX-API-DMAC10.html)
BR (1) BR9404842A (cg-RX-API-DMAC10.html)
CA (1) CA2137221C (cg-RX-API-DMAC10.html)
CO (1) CO4290427A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ290559B6 (cg-RX-API-DMAC10.html)
DE (1) DE69427017T2 (cg-RX-API-DMAC10.html)
DK (1) DK0657428T3 (cg-RX-API-DMAC10.html)
ES (1) ES2155844T3 (cg-RX-API-DMAC10.html)
FI (2) FI106455B (cg-RX-API-DMAC10.html)
GR (1) GR3036136T3 (cg-RX-API-DMAC10.html)
HU (1) HUT71489A (cg-RX-API-DMAC10.html)
IL (1) IL111843A (cg-RX-API-DMAC10.html)
MY (1) MY121543A (cg-RX-API-DMAC10.html)
NO (1) NO302884B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ270039A (cg-RX-API-DMAC10.html)
PE (1) PE41495A1 (cg-RX-API-DMAC10.html)
PL (1) PL181734B1 (cg-RX-API-DMAC10.html)
PT (1) PT657428E (cg-RX-API-DMAC10.html)
RU (1) RU2145958C1 (cg-RX-API-DMAC10.html)
SI (1) SI0657428T1 (cg-RX-API-DMAC10.html)
TW (1) TW290540B (cg-RX-API-DMAC10.html)
UA (1) UA52577C2 (cg-RX-API-DMAC10.html)
YU (2) YU49312B (cg-RX-API-DMAC10.html)
ZA (1) ZA949584B (cg-RX-API-DMAC10.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
US6794510B2 (en) * 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
CN1767830A (zh) * 2003-04-08 2006-05-03 普罗热尼奇制药公司 外周阿片拮抗剂具体是甲基纳曲酮治疗肠易激综合征的用途
EP2368553B1 (en) 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
JP4991312B2 (ja) * 2003-12-16 2012-08-01 ネクター セラピューティクス 化学修飾された小分子化合物
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
CN100579373C (zh) * 2004-06-04 2010-01-13 阿得罗公司 包含鸦片样物质拮抗剂的组合物
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
CN101262867A (zh) * 2005-07-01 2008-09-10 叶林发现公司 用于治疗肥胖的mao-b抑制剂
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
CN100383121C (zh) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺
US20090325857A1 (en) 2006-04-21 2009-12-31 Raphael Beumer Use of opioid receptor antagonists
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CA2670136A1 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. 7,8-saturated-4,5-epoxy-morphinanium analogs
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101429154B (zh) * 2008-11-14 2011-01-05 天津泰普药品科技发展有限公司 无水阿维莫泮及其药物组合物
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
DK2506712T3 (da) 2009-12-04 2019-06-03 Alkermes Pharma Ireland Ltd Morfinanderivater til behandling af lægemiddeloverdosering
WO2011161646A2 (en) 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
CN103360302B (zh) * 2012-03-29 2015-08-26 北大方正集团有限公司 阿维莫泮的纯化方法
WO2016064914A1 (en) 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
CA2998708C (en) 2015-10-01 2019-09-03 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
AU2018234911B2 (en) 2017-03-17 2024-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
WO2024090512A1 (ja) * 2022-10-27 2024-05-02 株式会社京都創薬研究所 ナフタレン誘導体の結晶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US5136040A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Preparation of substituted tetrahydropyridines
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists

Also Published As

Publication number Publication date
NO944644L (no) 1995-06-09
IL111843A (en) 2000-02-29
CN1111239A (zh) 1995-11-08
AU7917094A (en) 1995-06-15
CN1057294C (zh) 2000-10-11
FI106455B (fi) 2001-02-15
ZA949584B (en) 1996-06-03
JP3834075B2 (ja) 2006-10-18
CZ290559B6 (cs) 2002-08-14
YU82304A (sh) 2006-03-03
JPH07215937A (ja) 1995-08-15
ES2155844T3 (es) 2001-06-01
JP2006070042A (ja) 2006-03-16
NO944644D0 (no) 1994-12-02
RU2145958C1 (ru) 2000-02-27
CN1223257A (zh) 1999-07-21
RU94042903A (ru) 1996-10-27
AU681198B2 (en) 1997-08-21
EP0984004A3 (en) 2003-10-15
BR9404842A (pt) 1995-08-08
FI20000353L (fi) 2000-02-17
GR3036136T3 (en) 2001-09-28
KR950017957A (ko) 1995-07-22
PL306068A1 (en) 1995-06-12
CA2137221C (en) 2011-02-22
PE41495A1 (es) 1995-11-28
DE69427017D1 (de) 2001-05-10
CA2137221A1 (en) 1995-06-09
US5434171A (en) 1995-07-18
FI945703L (fi) 1995-06-09
KR100356239B1 (ko) 2002-12-26
SI0657428T1 (en) 2001-08-31
FI945703A0 (fi) 1994-12-02
EP0657428A1 (en) 1995-06-14
HK1013826A1 (en) 1999-09-10
EP1607387A3 (en) 2007-01-03
CZ299294A3 (en) 1995-10-18
NO302884B1 (no) 1998-05-04
PL181734B1 (pl) 2001-09-28
TW290540B (cg-RX-API-DMAC10.html) 1996-11-11
UA52577C2 (uk) 2003-01-15
DE69427017T2 (de) 2001-09-06
EP1607387A2 (en) 2005-12-21
EP0657428B1 (en) 2001-04-04
EP0984004A2 (en) 2000-03-08
HUT71489A (en) 1995-11-28
DK0657428T3 (da) 2001-05-07
YU49312B (sh) 2005-06-10
FI106860B (fi) 2001-04-30
HU9403466D0 (en) 1995-02-28
PT657428E (pt) 2001-07-31
MY121543A (en) 2006-02-28
YU70294A (sh) 1997-07-31
IL111843A0 (en) 1995-03-15
ATE200279T1 (de) 2001-04-15
CN1121387C (zh) 2003-09-17
CO4290427A1 (es) 1996-04-17

Similar Documents

Publication Publication Date Title
CA2137221C (en) Preparation of 3,4,4-trisubstituted piperidinyl-n-alkylcarboxylates and intermediates
US5250542A (en) Peripherally selective piperidine carboxylate opioid antagonists
KR100229117B1 (ko) 피페리딘 유도체
US5270328A (en) Peripherally selective piperidine opioid antagonists
JPH10101565A (ja) 胃腸血行障害を治療および予防するための医薬製剤を製造するためのベンズアゼピン−ｎ−酢酸誘導体の使用
US7091354B2 (en) Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
CA2064373C (en) Piperidine derivatives
ES2354968T3 (es) Derivados de piperidina antihistamínicos e intermedios para la preparación de los mismos.
HK1027558A (en) Trisubstituted-piperidinyl-n-alkylcarboxylates as opioid antagonists
HK1084950A (en) 3,4,4-trisubstituted piperidine derivatives and their use as opioid antagonists
HK1013826B (en) Preparation of 3,4,4-trisubstitutedpiperidinyl-n-alkylcarboxylates and intermediates, useful as opioid antagonists
EP1032561B1 (en) Substituted oximes as neurokinin antagonists
EP1278729B1 (en) Benzosuberonylpiperidine compounds as analgesics
US20090030041A1 (en) N-substituted N-(4-piperidinyl) Amide Derivative
EP3908574A1 (en) Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)- n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide
HU211916A9 (hu) Érzéstelenítőként alkalmazható N-fenil-N-(4-piperidinil)-amidok Az átmeneti oltalom az 1-29., 39., 46. és 47. igénypontra vonatkozik.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired